DOCSLIB.ORG

Genmab Announces Daratumumab and Ofatumumab Data to Be Included in 18 Presentations at American Society of Hematology Annual Meeting (ASH)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genmab Announces Daratumumab and Ofatumumab Data to Be Included in 18 Presentations at American Society of Hematology Annual Meeting (ASH) Genmab Announces Daratumumab and Ofatumumab Data to Be Included in 18 Presentations at American Society of Hematology Annual Meeting (ASH) Media Release 18 abstracts on Genmab programs scheduled for presentation at ASH 6 daratumumab oral presentations and 11 daratumumab poster presentations Key daratumumab abstracts: additional Phase III CASTOR & POLLUX data, Phase I subcutaneous formulation study, immuno-modulatory mechanisms of action, and ‘real life’ clinical practice daratumumab and pomalidomide retreatment data 1 ofatumumab poster presentation Copenhagen, Denmark; November 3, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that 17 daratumumab abstracts have been accepted for presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 3-6 in San Diego, California. The daratumumab abstracts are sponsored by our collaboration partner Janssen Biotech, Inc., with the exception of one that was based on an investigator-sponsored study, and one that used commercial daratumumab. One abstract on a study with ofatumumab has also been scheduled for a poster presentation at the meeting. All abstracts are available on the ASH website at www.hematology.org. A list of the key daratumumab abstracts is included below. “A number of presentations will highlight additional analyses and details from the daratumumab Phase III POLLUX and CASTOR studies that formed the basis of regulatory filings earlier this year. Additional presentations include the Phase I study of the subcutaneous formulation of daratumumab, data on the immuno-modulatory properties of daratumumab, and novel ‘real life’ clinical practice data on daratumumab plus pomalidomide retreatment of refractory multiple myeloma patients. We are excited that daratumumab will be featured in so many presentations at this key hematology conference,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. Key Daratumumab Abstracts Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR - Oral presentation Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of POLLUX - Oral presentation Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of POLLUX - Oral presentation Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone - Oral presentation Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO) - Oral presentation Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients – Oral presentation This is an independent study, not sponsored by Janssen. Genmab A/S Tel: +45 7020 2728 Media Release no. 09 Bredgade 34E Fax: +45 7020 2729 Page 1/2 1260 Copenhagen K, Denmark www.genmab.com CVR no. 2102 3884 Genmab Announces Daratumumab and Ofatumumab Data to Be Included in 18 Presentations at American Society of Hematology Annual Meeting (ASH) Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of CASTOR - Poster presentation Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T- Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) - Poster presentation High-parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation as a Novel Mechanism of Action - Poster presentation About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com. Contact: Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication T: +45 33 44 77 20; M: +45 25 12 62 60; E: [email protected] This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law. Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and ® ® ® UniBody . Arzerra is a trademark of Novartis AG or its affiliates. DARZALEX is a trademark of Janssen Biotech, Inc. Genmab A/S Tel: +45 7020 2728 Media Release no. 09 Bredgade 34E Fax: +45 7020 2729 Page 2/2 1260 Copenhagen K, Denmark www.genmab.com CVR no. 2102 3884 .
Load more

Recommended publications
  • Federal Register Notice 5-1-2020 Pdf Icon[PDF – 358
    Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices 25439 confidential by the respondent (5 U.S.C. schedules. Other than examination DEPARTMENT OF HEALTH AND 552(b)(4)). reports, it provides the only financial HUMAN SERVICES Current actions: The Board has data available for these corporations. temporarily revised the instructions to The Federal Reserve is solely Centers for Disease Control and the FR Y–9C report to accurately reflect responsible for authorizing, supervising, Prevention the revised definition of ‘‘savings and assigning ratings to Edges. The [CDC–2020–0046; NIOSH–233–C] deposits’’ in accordance with the Federal Reserve uses the data collected amendments to Regulation D in the on the FR 2886b to identify present and Hazardous Drugs: Draft NIOSH List of interim final rule published on April 28, potential problems and monitor and Hazardous Drugs in Healthcare 2020 (85 FR 23445). Specifically, the develop a better understanding of Settings, 2020; Procedures; and Risk Board has temporarily revised the activities within the industry. Management Information instructions on the FR Y–9C, Schedule HC–E, items 1(b), 1(c), 2(c) and glossary Legal authorization and AGENCY: Centers for Disease Control and content to remove the transfer or confidentiality: Sections 25 and 25A of Prevention, HHS. withdrawal limit. As a result of the the Federal Reserve Act authorize the ACTION: Notice and request for comment. revision, if a depository institution Federal Reserve to collect the FR 2886b chooses to suspend enforcement of the (12 U.S.C. 602, 625). The obligation to SUMMARY: The National Institute for six transfer limit on a ‘‘savings deposit,’’ report this information is mandatory.
    [Show full text]
  • ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
    cancers Article ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response Femke A. I. Ehlers 1,2,3 , Nicky A. Beelen 1,2,3, Michel van Gelder 2,3, Tom M. J. Evers 1,3,4, Marjolein L. Smidt 3,5, Loes F. S. Kooreman 3,6 , Gerard M. J. Bos 2,3 and Lotte Wieten 1,3,* 1 Department of Transplantation Immunology, Tissue Typing Laboratory, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands; [email protected] (F.A.I.E.); [email protected] (N.A.B.); [email protected] (T.M.J.E.) 2 Department of Internal Medicine, Division of Hematology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands; [email protected] (M.v.G.); [email protected] (G.M.J.B.) 3 GROW—School for Oncology and Developmental Biology, Maastricht University, 6229 GT Maastricht, The Netherlands; [email protected] (M.L.S.); [email protected] (L.F.S.K.) 4 Medical Systems Biophysics and Bioengineering, Leiden Academic Centre for Drug Research, Faculty of Science, Leiden University, 2333 CC Leiden, The Netherlands 5 Department of Surgery, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands 6 Department of Pathology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands * Correspondence: [email protected] Citation: Ehlers, F.A.I.; Beelen, N.A.; Simple Summary: Natural killer (NK) cells are potent killers of tumor cells. Many tumors, includ- van Gelder, M.; Evers, T.M.J.; Smidt, ing breast cancers, develop mechanisms to suppress anti-tumor immune responses, requiring the M.L.; Kooreman, L.F.S.; Bos, G.M.J.; development of strategies to overcome suppression.
    [Show full text]
  • Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
    Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma Company Announcement DARZALEX® (daratumumab) approved in Europe in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant Approval follows positive opinion by European Committee for Medicinal Products for Human Use (CHMP) in December Approval based on data from Phase III CASSIOPEIA study Copenhagen, Denmark; January 20, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for DARZALEX® (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). The EC approval follows a positive opinion issued for DARZALEX by the CHMP of the European Medicines Agency (EMA) in December 2019. In August 2012, Genmab granted Janssen Biotech, Inc. (Janssen) an exclusive worldwide license to develop, manufacture and commercialize daratumumab. “With this approval, newly diagnosed patients with multiple myeloma who are eligible for ASCT may have the opportunity for treatment with a DARZALEX-containing regimen. We are extremely pleased that DARZALEX has received this latest approval and we look forward to the combination of DARZALEX plus bortezomib, thalidomide and dexamethasone being launched in Europe,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. The approval was based on the Phase III CASSIOPEIA (MMY3006) study sponsored by the French Intergroupe Francophone du Myelome (IFM) in collaboration with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen R&D, LLC.
    [Show full text]
  • Daratumumab in Combination with Lenalidomide and Dexamethasone
    Emerging Treatment Paradigms in Multiple Myeloma: Targeting the Neighborhood and Beyond Kenneth C. Anderson, M.D. Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute;Kraft Family Professor of Medicine Harvard Medical School Consultant: Celgene, Bristol Myers Squibb, Millennium-Takeda, Sanofi-Aventis, Janssen, Gilead, Precision Biosciences, Tolero Scientific Founder: Oncopep, C4 Therapeutics Therapeutic Advances in Multiple Myeloma Proteasome inhibitors: bortezomib, carfilzomib, ixazomib; immunomodulatory drugs: thalidomide, lenalidomide, pomalidomide; HDAC inhibitor: panobinostat; monoclonal antibodies: elotuzumab daratumumab, and isatuximab; nuclear transport inhibitor: selinexor Target MM in the BM microenvironment, alone and in combination, to overcome conventional drug resistance in vitro and in vivo Effective in relapsed/refractory, relapsed, induction, consolidation, and maintenance therapy 27 FDA approvals and median patient survival prolonged 3-4 fold, from 3 to at least 8-10 years, and MM is a chronic illness In many patients. In 2019: 32,110 new cases: 18,130 men, 13,980 women 12,960 deaths: 6990 men, 5970 women Even without CRAB (Calcium, Renal, Anemia, Bone) Myeloma Defining Events (IMWG) Include: Bone marrow plasma cells > 60% Abnormal FLC ratio > 100 (involved kappa) or <0.01 (involved lambda) Focal bone marrow lesions on PET-CT and/or MRI Treat as MM High Risk Smoldering MM (SMM) > 2 factors: M protein >2gm/dL, BM plasma cells > 20%, FLC ratio >20) Protocols of novel agents/immune therapies to delay or prevent progression of high risk SMM to active MM. Rajkumar et al. Lancet Oncol 2015; 12:e538-e548 Kumar et al Blood Cancer J 2018; 59 Continuous Lenalidomide (25 mg d1-21 of 28 d) vs Observation in SMM using Mayo 2018 Risk Criteria (>20% plasma cells, M protein> 2gm/dL, serum free lite chain ratio >20) High Risk Intermediate Risk Low Risk Decreased progression of high risk SMM to to MM 11.4% vs 3.4% secondary malignancies 51% discontinuation rate No OS difference Lonial et al J Clin Oncol 2020;38:1126-37.
    [Show full text]
  • Complement Activation in the Treatment of B-Cell Malignancies
    antibodies Review Complement Activation in the Treatment of B-Cell Malignancies Clive S. Zent 1,* , Jonathan J. Pinney 2,3, Charles C. Chu 1 and Michael R. Elliott 2,3 1 Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA; [email protected] 2 Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA; [email protected] (J.J.P.); [email protected] (M.R.E.) 3 Center for Cell Clearance, University of Virginia, Charlottesville, VA 22908, USA * Correspondence: [email protected]; Tel.: +1-585-276-6891 Received: 15 September 2020; Accepted: 22 November 2020; Published: 1 December 2020 Abstract: Unconjugated monoclonal antibodies (mAb) have revolutionized the treatment of B-cell malignancies. These targeted drugs can activate innate immune cytotoxicity for therapeutic benefit. mAb activation of the complement cascade results in complement-dependent cytotoxicity (CDC) and complement receptor-mediated antibody-dependent cellular phagocytosis (cADCP). Clinical and laboratory studies have showed that CDC is therapeutically important. In contrast, the biological role and clinical effects of cADCP are less well understood. This review summarizes the available data on the role of complement activation in the treatment of mature B-cell malignancies and proposes future research directions that could be useful in optimizing the efficacy of this important class of drugs. Keywords: complement; cytotoxicity; phagocytosis; monoclonal antibody; B-cell lymphoma; chronic lymphocytic leukemia (CLL) 1. Introduction Unconjugated monoclonal antibodies (mAb) have an important clinical role in the management of mature B-cell malignancies [1–5]. The major mechanism of action of the mAbs targeting CD20, CD38, and CD52 surface antigens on B cells is activation of innate immune cytotoxicity.
    [Show full text]
  • Belamaf) in Combination with Bortezomib/Dexamethasone (Vd) in Relapsed/Refractory Multiple Myeloma (RRMM
    DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (Vd) in Relapsed/Refractory Multiple Myeloma (RRMM) Rakesh Popat,1 Ajay Nooka,2 Keith Stockerl‐Goldstein,3 Rafat Abonour,4 Ryan Ramaekers,5 Amit Khot,6 Adam Forbes,7 Cindy Lee,8 Bradley Augustson,9 Andrew Spencer,10 Maria Victoria Mateos,11 Bikramjit Chopra,12 Rachel Rogers,13 Deborah A. Smith,14 Jacqueline Davidge,12 Rocio Montes de Oca,13 Geraldine Ferron‐Brady,13 Anne Yeakey,13 Mala Talekar,13 Brandon E. Kremer,13 Ira Gupta,13 Hang Quach,15 1University College London Hospitals, NHS Foundation Trust, London, UK; 2Emory University, Winship Cancer Institute, Atlanta, GA, USA; 3Washington University Medical School, St. Louis, MO, USA; 4Queen Elizabeth Hospital, Adelaide, SA, Australia; 5CHI Health St Francis Cancer Treatment Center, Grand Island, NE, USA; 6Peter MacCallum Cancer Centre and Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia; 7Royal Cornwall Hospital, Truro, Cornwall, UK; 8Department of Haematology, Queen Elizabeth Hospital, Adelaide, SA, Australia; 9Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia; 10Department of Haematology, The Alfred Hospital, Melbourne, VIC, Australia; 11University Hospital of Salamanca‐Instituto de Investigación Biomédica de Salamanca, Cancer Research Center‐IBMCC (USAL‐CSIC), Salamanca, Spain; 12GlaxoSmithKline (GSK), Uxbridge, Middlesex, UK; 13GSK, Upper Providence, PA, USA; 14GSK, Waltham, MA, USA; 15University
    [Show full text]
  • Prior Authorization Updates for Specialty Pharmacy
    Provider Bulletin July 2021 Medical drug benefit Clinical Criteria updates On February 19, 2021, and March 4, 2021, the Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Healthy Blue. These policies were developed, revised or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: • New: newly published criteria • Revised: addition or removal of medical necessity requirements, new document number • Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive Please share this notice with other members of your practice and office staff. Note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services. Effective date Document number Clinical Criteria title New or revised September 25, 2021 ING-CC-0186* Margenza (margetuximab-cmkb) New September 25, 2021 ING-CC-0187* Breyanzi (lisocabtagene maraleucel) New September 25, 2021 ING-CC-0189* Amondys 45 (casimersen) New September 25, 2021 ING-CC-0190* Nulibry (fosdenopterin) New September 25, 2021 ING-CC-0086* Spravato (esketamine) Nasal Spray Revised September 25, 2021 ING-CC-0158 Enhertu (fam-trastuzumab deruxtecan-nxki) Revised Rituximab Agents for Oncologic Indications September
    [Show full text]
  • Daratumumab, a Cd38 Monoclonal Antibody in Patients with Multiple Myeloma - Preliminary Efficacy and Pharmacokinetics Data from a Dose-Escalation Phase I/Ii Study
    Abstract #1143 DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - PRELIMINARY EFFICACY AND PHARMACOKINETICS DATA FROM A DOSE-ESCALATION PHASE I/II STUDY Lokhorst H, Gimsing P, Nahi H, Richardson P, Lisby S, Plesner T 1 My disclosures • Genmab: Research support, advisory board • Celgene: Research support, speaker’s fee • Janssen-Cilag: Speaker’s fee • Mundipharma: Advisory Board Daratumumab 3 Daratumumab A human CD38 mAb with broad-spectrum killing activity 4 Daratumumab: GEN501 Phase I/II Study of Monotherapy in Relapsed and Relapsed - Refractory Multiple Myeloma Objectives Primary Establishment of the safety profile of daratumumab Secondary To establish the pharmacokinetic profile of daratumumab Evaluation of the efficacy of daratumumab according to International Myeloma Workshop Consensus Panel 1, Blood 2011;117:4691-5 Evaluation of the immunogenicity of daratumumab 5 Inclusion Criteria Main inclusion criteria Patients with advanced Multiple Myeloma requiring systemic therapy Relapsed or refractory disease with at least 2 prior lines of therapy and without further established treatment options ECOG performance status of 0-2 Patients having a life expectancy > 3 months 6 Patient Characteristics Number of Number of 2 2 1 2 Cohort Age1 Len Thal2 Bor Dex/Pred Chemo2,3 ASCT patients treatments1 63 5 ≤1 mg/kg 17 15 12 17 15/7 17 11 (42-76) (2-8) 64 8 2 mg/kg 3 3 3 3 3/3 3 3 (60-71) (6-10) 64 6 4 mg/kg 3 3 1 3 3/1 3 2 (62-66) (3-6) 60 11 8 mg/kg 3 3 2 3 3/2 3 3 (56-68) (5-12) 55 7 16 mg/kg 3 2 2 3 3 1 3 3 (54-59) (4-8) 1: Data are in median (range) 2: Number of patients exposed to the drug/treatment 3: vincristine, doxorubicin, cyclophosphamide, melphalan and others Results are based on data before database lock 7 Daratumumab Trial Design Part 1 Open label, weekly i.v.
    [Show full text]
  • Belantamab Mafodotin to Treat Multiple Myeloma: a Comprehensive Review of Disease, Drug Efficacy and Side Effects
    Review Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects Grace Lassiter 1,*, Cole Bergeron 2, Ryan Guedry 2, Julia Cucarola 2, Adam M. Kaye 3 , Elyse M. Cornett 4, Alan D. Kaye 4 , Giustino Varrassi 5, Omar Viswanath 4,6,7,8 and Ivan Urits 4,9 1 School of Medicine, Georgetown University, Washington, DC 20007, USA 2 School of Medicine, Louisiana State University Shreveport, Shreveport, LA 71103, USA; [email protected] (C.B.); [email protected] (R.G.); [email protected] (J.C.) 3 Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA; akaye@pacific.edu 4 Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA; [email protected] (E.M.C.); [email protected] (A.D.K.); [email protected] (O.V.); [email protected] (I.U.) 5 Paolo Procacci Foundation, Via Tacito 7, 00193 Roma, Italy; [email protected] 6 College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85724, USA 7 Department of Anesthesiology, School of Medicine, Creighton University, Omaha, NE 68124, USA 8 Valley Anesthesiology and Pain Consultants—Envision Physician Services, Phoenix, AZ 85004, USA 9 Southcoast Health, Southcoast Physicians Group Pain Medicine, Wareham, MA 02571, USA * Correspondence: [email protected] Received: 14 December 2020; Accepted: 18 January 2021; Published: 21 January 2021 Abstract: Multiple myeloma (MM) is a hematologic malignancy characterized by excessive clonal proliferation of plasma cells. The treatment of multiple myeloma presents a variety of unique challenges due to the complex molecular pathophysiology and incurable status of the disease at this time.
    [Show full text]
  • Roche Analyst Event Monday, 5 December 2016 This Presentation Contains Certain Forward-Looking Statements
    58th ASH Annual Meeting, San Diego Roche Analyst Event Monday, 5 December 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]
  • Immune Therapies for Hematologic Malignancies
    cancers Editorial Immune Therapies for Hematologic Malignancies Matthew J. Olnes 1,2 1 Hematology and Medical Oncology, Alaska Native Tribal Health Consortium, 3900 Ambassador Dr., Anchorage, AK 99508, USA; [email protected]; Tel.: +1-907-729-1180; Fax: +1-907-729-1189 2 WWAMI School of Medical Education, University of Alaska Anchorage, 3211 Providence Drive, Anchorage, AK 99508, USA The era of immunotherapy for hematologic malignancies began with the first allo- geneic hematopoietic stem cell transplant (HSCT) study published by E. Donnall Thomas in 1957 [1]. Since then, the field of malignant hematology has been at the forefront of the clinical application of immune therapies. Allogeneic HSCT remains a standard treatment for acute leukemias and relapsed or refractory high-grade lymphomas, as well as select patients with relapsed and refractory indolent non-Hodgkin lymphomas and multiple myeloma. A key component of this therapy is the presence of allogeneic donor T-cells that provide long lasting immune surveillance and graft versus tumor effects. Some newer developments that have improved clinical outcomes include HSCT protocols that expand the pool of eligible donors with haploidentical grafts [2], and manipulations such as T-cell depletion to minimize rejection and graft versus host disease [3]. Allogeneic HSCT is the only curative treatment for myelodysplastic syndromes (MDS). Hypomethylating agents, lenolidomide, and luspatercept play an important role in man- aging this disease, but relapses invariably occur. Patients with low and intermediate risk MDS exhibit an increased oligoclonal expansion of autoreactive CD8+ T-cells which mount an immune assault on bone marrow progenitors, as well as reduced T helper 2 (T 2) and H regulatory T-cell (T-reg) responses which favor autoimmunity [4,5].
    [Show full text]
  • Clinical Criteria Updates for Specialty Pharmacy
    MAINE Provider Communications Clinical criteria updates for specialty pharmacy Published: Nov 1, 2019 - Products & Programs / Pharmacy The following clinical criteria documents were endorsed at the August 16, 2019 clinical criteria meeting. To access the clinical criteria information please click here. If you do not have access to the internet, you may request a hard copy of any updated policy by contacting the Provider Call Center. Revised clinical criteria effective September 23, 2019 (The following clinical criteria was revised to expand medical necessity indications or criteria.) ING-CC-0011 Ocrevus (ocrelizumab) ING-CC-0014 Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis ING-CC-0027 Denosumab Agents ING-CC-0028 Benlysta (belimumab) ING-CC-0029 Dupixent (dupilumab) ING-CC-0030 Implantable and ER Buprenorphine Containing Agents ING-CC-0038 Human Parathyroid Hormone Agents ING-CC-0041 Complement Inhibitors ING-CC-0075 Rituximab Agents for Non-Oncology Indications ING-CC-0082 Onpattro (patisiran) ING-CC-0105 Vectibix (panitumumab) ING-CC-0114 Jevtana (cabazitaxel) ING-CC-0124 Keytruda (pembrolizumab) ING-CC-0127 Darzalex (daratumumab) ING-CC-0128 Tecentriq (atezolizumab) ING-CC-0134 Provenge (sipuleucel-T) Revised clinical criteria effective September 23, 2019 (The following clinical criteria were reviewed and may have word changes or clarifications, but had no significant changes to the medical necessity indications or criteria.) ING-CC-0004 H.P. Acthar Gel (repository corticotropin injection) ING-CC-0008
    [Show full text]